DDN: micro-cap pharmaceutical distributor with limited upside and elevated execution risk
Intrinsic value VND 9,124 vs market VND 9,000 — implied upside 1.4% (confidence: very_low).
Tổng quan doanh nghiệp
Công ty Cổ phần Dược - Thiết bị y tế Đà Nẵng (DDN) is a small-cap pharmaceutical and medical equipment company listed on UPCOM with 16,116,383 shares outstanding. The company operates in the Vietnamese pharmaceuticals distribution/retail segment (ICB: Dược phẩm) and generates revenues from medicine and medical-device sales. Reported revenues were VND 1,392.7 bn in 2024 and VND 1,067.9 bn in 2025, after VND 943.4 bn in 2023, reflecting a volatile top line over the last three years.
Luận điểm đầu tư
DDN's valuation implies essentially no margin of safety: the blended intrinsic value per share is VND 9,124 versus the last match price of VND 9,000 (1.4% upside) and model confidence is very_low. Fundamental performance is weak — ROE of 2.0% and ROA of 0.4% (latest) signal low capital efficiency versus typical peers; net profit margin is near breakeven at 0.4% while gross margin is 8.9%. Leverage is high with Debt/Equity of 3.93x, and net debt reported in the DCF inputs is VND 113,412,668,082 (model input).
The DCF/PE blend driving the intrinsic value has notable sanity issues that reduce conviction: the DCF component shows an anomalous dcf_intrinsic of -179.3 (model inputs), while the PE-based raw intrinsic is VND 3,470.8 per share and the blended result after isotonic calibration is VND 9,124. WACC is set at 10.0% with a terminal growth of 4.0% and a fair PE of 13.69. Given the combination of a distorted DCF output, low earnings quality (score 29.5), illiquidity, 0% foreign ownership room and a dominant majority shareholder (Công ty Cổ phần Megram owning 51.01%), the upside is too narrow to compensate for execution and model risk.
Bình luận định giá
Blended DCF and PE model (70% DCF / 30% PE) with isotonic calibration to produce the intrinsic value.
- WACC 10.0% and terminal growth 4.0% (model_inputs.wacc, terminal_g)
- PE component using fair PE 13.69 and PE cap 25 (model_inputs.fair_pe, pe_cap)
- Large share of terminal value: TV_pct 57.07% of enterprise value (model_inputs.tv_pct)
- Sanity flags: DCF output anomaly dcf_intrinsic -179.3 and sanities ['illiquid','low_earnings_quality']
- Net debt used in valuation: VND 113,412,668,082 (model_inputs.net_debt)
The blended intrinsic of VND 9,124 implies negligible upside to the market price and model confidence is very_low, so the valuation is highly uncertain. The negative DCF output and heavy reliance on the PE-side calibration reduce our confidence in the intrinsic estimate; treat the target as a low-conviction reference rather than a precise fair value.
Quan điểm tích cực và tiêu cực
- Stable revenue base of VND 1,392.7 bn in 2024 indicates the company can generate scale in its local market.
- Low P/B at 0.7x suggests some asset-backed upside if profitability and ROE can be improved.
- Presence of institutional controlling shareholder (Megram 51.01%) could support strategic stability or consolidation.
- Very low earnings quality score (29.5) and DCF anomaly (dcf_intrinsic -179.3) point to questionable earnings reliability.
- Profitability is weak: ROE 2.0%, net margin 0.4%, EPS VND 254 despite P/E of 35.5x — valuation multiple appears disconnected from fundamentals.
- High leverage with Debt/Equity 3.93x and reported net debt in model inputs increases solvency risk in a downturn.
- Liquidity and marketability risks: avg daily volume ~10,792 shares (2-week) and sanities flag 'illiquid'; foreign_room is 0.0%, limiting demand from foreign investors.
Bối cảnh ngành
The Vietnamese pharmaceutical distribution sector faces margin pressure from competitive pricing and regulatory oversight. VAS accounting and inventory/lifecycle management in pharma can distort short-term earnings — items like trade discounts, returns and inventory provisions are treated differently under VAS versus IFRS and can affect reported margins and earnings quality. State-related policies (SBV credit guidance) and bank asset restructurings (VAMC bonds) can indirectly affect small distributors through working-capital funding availability. Peers in our coverage show a median implied upside of 12.1% — DDN's 1.4% sits well below that peer median, and several top peers display materially higher conviction and upside.
Yếu tố rủi ro
- Low earnings quality (score 29.5) — reported profits may be volatile or contain one-off elements.
- High leverage: Debt/Equity 3.93x increases refinancing and solvency risk if margins compress.
- Illiquidity and zero foreign room (foreign_room 0.0%) — trading constraints may widen bid-ask and hinder price discovery.
- Concentrated ownership: Megram holds 51.01% which can limit free float and minority liquidity; related-party or strategic control risks exist.
- DCF model anomaly: dcf_intrinsic = -179.3 indicates the cash-flow projection or adjustment inputs are unstable.
- Negative recent revenue momentum: Revenue YoY -23.3% (latest) and net profit fell from VND 7.6 bn in 2024 to VND 4.1 bn in 2025.
- Small market cap and UPCOM listing — lower regulatory disclosure and analyst coverage relative to HSX/HNX-listed peers.
Yếu tố xúc tác
- Improvement in net margin or a sustainable recovery in revenue growth reversing the -23.3% decline would re-rate ROE and EPS.
- Corporate actions by the majority shareholder (Megram) such as capital injection, M&A or a plan to list on a mainboard could unlock value.
- Reduction in leverage or a restructuring that materially lowers Debt/Equity would reduce solvency risk and improve investor sentiment.
Đánh giá pháp y tài chính
No Beneish M-Score is available (mscore null), so there is no explicit manipulation signal from that test. However, earnings quality is low (29.5) and the model's sanity flags include 'low_earnings_quality' and 'illiquid', which together are the primary forensic concerns. Given the DCF anomaly (dcf_intrinsic -179.3) and volatility in reported profits (net profit VND 7.6 bn in 2024 -> VND 4.1 bn in 2025), investors should treat reported earnings with caution and seek supporting detail in cash flow and working-capital notes.
Lịch sử dự báo
The model's historical track record across 12 years shows a hit rate of 27.3% (years where >10% upside calls correctly predicted next-year direction), which is materially below a coin-flip. Average realized upside when correct is high (avg_upside_pct 132.9%) but the low hit rate and the current model confidence of very_low suggest the historical performance provides limited comfort for this specific valuation.
Được viết bởi mô hình ngôn ngữ ngày 2026-08-10 dựa trên kết quả mô hình và báo cáo tài chính của chính trang này, và có thể trích dẫn số liệu tại thời điểm đó. Đây là phân tích mô tả, không phải khuyến nghị đầu tư — không đưa ra hay hàm ý bất kỳ khuyến nghị mua, bán hay nắm giữ nào.